This study identifies therapeutic targeting of PIKfyve as a strategy to upregulate surface expression of MHC-I in cancer cells and thus enhance response to immunotherapies across various cancer types, including those such as pancreatic cancer that are often unresponsive to immunotherapies. The gene discussed is PIKFYVE; the disease is familial pancreatic carcinoma.